AstraZeneca’s tezelpelumab was granted orphan drug designation by FDA for the treatment of eosinophilic esophagitis.
Astrazeneca announced on Oct. 8, 2021that FDA granted its drug, tezepelumab, orphan drug designation for the treatment of eosinophilic esophagitis (EoE). EoE is a rare, chronic, inflammatory disease that has no approved treatments to date.
EoE occurs when eosinophils, a type of white blood cell, accumulate in the esophagus. If left untreated, it can make eating difficult or uncomfortable, leading to chronic pain, difficulty swallowing, poor growth, malnutrition, and weight loss. Other cells, including mast cells, T-cells, and fibroblasts, may also drive injury, inflammation, and detrimental tissue remodeling.
According to a company press release, tezepelumab is a monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP), a key epithelial cytokine that sits at the top of multiple inflammatory cascades. The intent behind blocking TSLP is to prevent pro-inflammatory cytokines by immune cells, which are implicated in many epithelial disease pathophysiologies.
“Eosinophilic esophagitis is a rare disease which involves a range of inflammatory cells that contribute to debilitating symptoms for patients, including severe pain and difficulty swallowing food,” said Mene Pangalos, executive vice-president, BioPharmaceuticals R&D, AstraZeneca, in the press release. “We are hopeful that tezepelumab, with its unique mechanism of action that targets the top of the inflammatory cascade, could become a potential new medicine to improve outcomes for these patients.”
AstraZeneca entered into a collaboration agreement with Amgen to develop tezepelumab in 2020. According to the press release, AstraZeneca leads development, while Amgen oversees the manufacturing process.
Source: AstraZeneca
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.